Trial Profile

Compassionate use study of VMT-a-NET

Status: Active, no longer recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 203Pb VMT alpha NET (Primary)
Indications Neuroendocrine tumours
Focus Therapeutic Use

Most Recent Events

25 Jan 2023 New trial record
23 Jan 2023 According to a ViewPoint Therapeutics media release, VMT-a-NET was administered under the supervision of the patients doctor, Dr. Ishida Sen MBBS MBBS, Director and Head of Nuclear Medicine at Fortis Hospital, New Delhi, in partnership with BJ Madan, a diagnostic & therapeutic radiopharmaceutical company in New Delhi. The progress of these patients will be followed by Dr. Sen and her team over the coming months.
23 Jan 2023 Results published in the ViewPoint Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com